DSP Healthcare Fund
An open ended equity scheme investing in healthcare and pharmaceutical sector
DSP Healthcare Fund
An open ended equity scheme investing in healthcare and pharmaceutical sector

Fund Manager

Aditya Khemka
Total work experience of 11 years.
Managing this Scheme since November 2018.

Vinit Sambre
Total work experience of 19 years.
Managing this Scheme since November 2018.

Jay Kothari (Dedicated Fund Manager for overseas investments)
Total work experience of 14 years.
Managing this Scheme since November 2018.

Inception date

Nov 30, 2018

Benchmark

S&P BSE HEALTHCARE (TRI)

NAV AS ON JULY 31, 2020
Regular Plan  
Growth: ₹ 15.386
Direct Plan  
Growth: ₹ 15.852
Total aum

₹ 571 Cr

Monthly average aum

₹ 512 Cr

Portfolio Turnover Ratio(Last 12 months):

0.18

Month End Expense Ratio
Regular Plan : 2.59%
Direct Plan : 1.01%

Exit Load

Holding period <12 months: 1%
Holding period >=12 months: Nil

Name of Instrument% to Net Assets
EQUITY & EQUITY RELATED
Listed / awaiting listing on the stock exchanges
Pharmaceuticals 71.33
✔ IPCA Laboratories Limited 9.34
✔ Dr. Reddy's Laboratories Limited 9.06
✔ JB Chemicals & Pharmaceuticals Limited 7.17
✔ Divi's Laboratories Limited 7.06
✔ Cipla Limited 5.78
✔ Aarti Drugs Limited 4.87
✔ Jubilant Life Sciences Limited 4.29
✔ Torrent Pharmaceuticals Limited 3.55
✔ Indoco Remedies Limited 3.29
Alembic Pharmaceuticals Limited 3.19
Procter & Gamble Health Limited 3.14
Unichem Laboratories Limited 2.71
Syngene International Limited 2.69
Alkem Laboratories Limited 1.92
Abbott India Limited 1.72
Ajanta Pharma Limited 1.55
Healthcare Services 10.93
Dr. Lal Path Labs Ltd. 2.99
Narayana Hrudayalaya Ltd. 2.81
Apollo Hospitals Enterprise Limited 2.77
Max Healthcare Institute Ltd^ 1.65
Advaita Allied Health Services Limited^ 0.71
Finance 3.28
✔ ICICI Lombard General Insurance Company Limited 3.28
Total 85.54
Foreign Securities and/or overseas ETF(s)
Listed / awaiting listing on the stock exchanges
Pharmaceuticals 5.90
Abbott Laboratories 3.05
Intuitive Surgical Inc 2.85
Healthcare Services 2.55
Abiomed Inc 2.55
Total 8.45
MONEY MARKET INSTRUMENTS
TREPS / Reverse Repo Investments / Corporate Debt Repo 6.05
Total 6.05
Cash & Cash Equivalent
Net Receivables/Payables -0.04
Total -0.04
GRAND TOTAL 100.00

✔ Top Ten Holdings
^ Pending Listing


 
Positions Increased
Finance
ICICI Lombard General Insurance Company Limited
Pharmaceuticals
Alkem Laboratories Limited
Cipla Limited
Dr. Reddy's Laboratories Limited
Syngene International Limited
Healthcare Services
Apollo Hospitals Enterprise Limited
Note: The above position change is compared to last month-end data.
Rebalances below 0.05 % are not considered.

Investment Objective

The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
However, there can be no assurance that the investment objective of the scheme will be realized.

Product Labelling

This open ended equity Scheme is suitable for investors who are seeking*
• Long term capital growth
• Investment in equity and equity related Securities of healthcare and pharmaceutical companies

* Investors should consult their financial advisors if in doubt whether the product is suitable for them.